Early Thrombotic Microangiopathy After ABO-Incompatible Living Donor Kidney Transplantation

Introduction: Although long-term graft survival is comparable with that of ABO-compatible (ABOc) renal transplantation, the risk of antibody-mediated rejection (ABMR) following ABO-incompatible (ABOi) transplantation is higher and can occur as an early thrombotic microangiopathy (TMA). Methods: We d...

Full description

Saved in:
Bibliographic Details
Main Authors: Dominique Bertrand, Arnaud Del Bello, Rebecca Sberro Soussan, Sophie Caillard, Guillaume Claisse, Lionel Couzi, Sophie Girerd, Alexandre Hertig, Yannick Le Meur, Vincent Pernin, Coralie Poulain, Cédric Rafat, Marie Matignon, Arnaud Buteux, Arnaud François, Mathilde Lemoine, Charlotte Laurent, Nassim Kamar, Tristan de Nattes, Dominique Guerrot
Format: Article
Language:English
Published: Elsevier 2025-03-01
Series:Kidney International Reports
Subjects:
Online Access:http://www.sciencedirect.com/science/article/pii/S2468024924034776
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849335863993958400
author Dominique Bertrand
Arnaud Del Bello
Rebecca Sberro Soussan
Sophie Caillard
Guillaume Claisse
Lionel Couzi
Sophie Girerd
Alexandre Hertig
Yannick Le Meur
Vincent Pernin
Coralie Poulain
Cédric Rafat
Marie Matignon
Arnaud Buteux
Arnaud François
Mathilde Lemoine
Charlotte Laurent
Nassim Kamar
Tristan de Nattes
Dominique Guerrot
author_facet Dominique Bertrand
Arnaud Del Bello
Rebecca Sberro Soussan
Sophie Caillard
Guillaume Claisse
Lionel Couzi
Sophie Girerd
Alexandre Hertig
Yannick Le Meur
Vincent Pernin
Coralie Poulain
Cédric Rafat
Marie Matignon
Arnaud Buteux
Arnaud François
Mathilde Lemoine
Charlotte Laurent
Nassim Kamar
Tristan de Nattes
Dominique Guerrot
author_sort Dominique Bertrand
collection DOAJ
description Introduction: Although long-term graft survival is comparable with that of ABO-compatible (ABOc) renal transplantation, the risk of antibody-mediated rejection (ABMR) following ABO-incompatible (ABOi) transplantation is higher and can occur as an early thrombotic microangiopathy (TMA). Methods: We designed a retrospective multicenter study, including all patients who presented with a TMA (histological and/or biological) after an ABOi transplantation (< 1 month) and compared with matched controls who had a favorable initial course with a normal biopsy. Results: Between 2013 and 2022, 375 ABOi kidney transplants were performed and 23 patients (6.1%) developed TMA (median: 1 day, interquartile range [IQR]: 0–3 days). Twenty-one patients (91.3%) had biological TMA. Among 23 early graft biopsies, histological evidence of active TMA was found in 17 cases (80.9%). All patients received treatment: 20 of 23 received at least 1 session of plasmapheresis and 19 of 23 received at least 1 injection of eculizumab. Eight early graft losses (30.4%) occurred (median: 7 days, IQR: 3–16 days). IgG and IgM anti–blood group antibody (ABGA) levels (peak and last pregraft assay) were significantly higher in the TMA group (peak: P = 0.01 for IgG and P = 0.0006 for IgM; last assay before kidney transplantation [KT]: P < 0.0001 for IgG and P = 0.0003 for IgM). A level ≥ 1/8 for IgG and ≥ 1/4 or IgM before transplantation were significantly and independently predictive of the occurrence of TMA. No other predictive factors were found. Conclusion: TMA after ABOi transplantation is not a rare phenomenon and is associated with a poor prognosis in nonresponders-to-treatment patients. ABGA titer performed by hemagglutination is an imperfect marker of the occurrence of such a phenomenon.
format Article
id doaj-art-b8b8a5d892624a71ac8022e7baa7eca3
institution Kabale University
issn 2468-0249
language English
publishDate 2025-03-01
publisher Elsevier
record_format Article
series Kidney International Reports
spelling doaj-art-b8b8a5d892624a71ac8022e7baa7eca32025-08-20T03:45:08ZengElsevierKidney International Reports2468-02492025-03-0110382883710.1016/j.ekir.2024.12.031Early Thrombotic Microangiopathy After ABO-Incompatible Living Donor Kidney TransplantationDominique Bertrand0Arnaud Del Bello1Rebecca Sberro Soussan2Sophie Caillard3Guillaume Claisse4Lionel Couzi5Sophie Girerd6Alexandre Hertig7Yannick Le Meur8Vincent Pernin9Coralie Poulain10Cédric Rafat11Marie Matignon12Arnaud Buteux13Arnaud François14Mathilde Lemoine15Charlotte Laurent16Nassim Kamar17Tristan de Nattes18Dominique Guerrot19Department of Nephrology, Kidney Transplantation and Hemodialysis, Rouen University Hospital, Rouen, France; Correspondence: Dominique Bertrand, 1 rue de Germont, Rouen University Hospital, Rouen, France.Nephrology and Organ Transplantation Department, Rangueil Toulouse University Hospital, Toulouse, FranceNecker-Enfants Malades Institute, French National Institute of Health and Medical Research, Paris, FranceNephrology and Transplantation Department, Strasbourg University Hospital, Strasbourg, FranceNephrology, Dialysis and Renal Transplantation Department, Hôpital Nord, CHU de Saint-Etienne, Jean Monnet University, Université de Lyon, Saint-Etienne, FranceDepartment of Nephrology, Kidney Transplantation and Hemodialysis, Bordeaux University Hospital, Rouen, FranceDepartment of Nephrology, Kidney Transplantation and Hemodialysis, Nancy University Hospital, Rouen, FranceDepartment of Nephrology, Kidney Transplantation and Hemodialysis, Foch Hospital, Suresnes, FranceDepartment of Nephrology, Kidney Transplantation and Hemodialysis, Brest University Hospital, Rouen, FranceDepartment of Nephrology, Kidney Transplantation and Hemodialysis, Montpellier University Hospital, Rouen, FranceDepartment of Nephrology, Kidney Transplantation and Hemodialysis, Amiens University Hospital, Rouen, FranceSoins Intensifs de Néphrologie et Rein Aigu, Hôpital Tenon, Assistance Publique - Hôpitaux de Paris, Paris, FranceDepartment of Nephrology, Kidney Transplantation and Hemodialysis, Hôpital Henri Mondor, Assistance Publique-Hôpitaux de Paris, Créteil, FranceEFS Etablissement Français du Sang, Rouen University Hospital, Rouen, FranceService d'anatomopathologie, Rouen University Hospital, Rouen, FranceDepartment of Nephrology, Kidney Transplantation and Hemodialysis, Rouen University Hospital, Rouen, FranceDepartment of Nephrology, Kidney Transplantation and Hemodialysis, Rouen University Hospital, Rouen, FranceNephrology and Organ Transplantation Department, Rangueil Toulouse University Hospital, Toulouse, FranceDepartment of Nephrology, INSERM U1234, CHU Rouen, Nephrology Department, Universite Rouen Normandie, Rouen, FranceDepartment of Nephrology, INSERM U1096, CHU Rouen, Universite Rouen Normandie, Rouen, FranceIntroduction: Although long-term graft survival is comparable with that of ABO-compatible (ABOc) renal transplantation, the risk of antibody-mediated rejection (ABMR) following ABO-incompatible (ABOi) transplantation is higher and can occur as an early thrombotic microangiopathy (TMA). Methods: We designed a retrospective multicenter study, including all patients who presented with a TMA (histological and/or biological) after an ABOi transplantation (< 1 month) and compared with matched controls who had a favorable initial course with a normal biopsy. Results: Between 2013 and 2022, 375 ABOi kidney transplants were performed and 23 patients (6.1%) developed TMA (median: 1 day, interquartile range [IQR]: 0–3 days). Twenty-one patients (91.3%) had biological TMA. Among 23 early graft biopsies, histological evidence of active TMA was found in 17 cases (80.9%). All patients received treatment: 20 of 23 received at least 1 session of plasmapheresis and 19 of 23 received at least 1 injection of eculizumab. Eight early graft losses (30.4%) occurred (median: 7 days, IQR: 3–16 days). IgG and IgM anti–blood group antibody (ABGA) levels (peak and last pregraft assay) were significantly higher in the TMA group (peak: P = 0.01 for IgG and P = 0.0006 for IgM; last assay before kidney transplantation [KT]: P < 0.0001 for IgG and P = 0.0003 for IgM). A level ≥ 1/8 for IgG and ≥ 1/4 or IgM before transplantation were significantly and independently predictive of the occurrence of TMA. No other predictive factors were found. Conclusion: TMA after ABOi transplantation is not a rare phenomenon and is associated with a poor prognosis in nonresponders-to-treatment patients. ABGA titer performed by hemagglutination is an imperfect marker of the occurrence of such a phenomenon.http://www.sciencedirect.com/science/article/pii/S2468024924034776ABO-incompatibleantibody-mediated rejectioneculizumabkidney transplantationthrombotic microangiopathy
spellingShingle Dominique Bertrand
Arnaud Del Bello
Rebecca Sberro Soussan
Sophie Caillard
Guillaume Claisse
Lionel Couzi
Sophie Girerd
Alexandre Hertig
Yannick Le Meur
Vincent Pernin
Coralie Poulain
Cédric Rafat
Marie Matignon
Arnaud Buteux
Arnaud François
Mathilde Lemoine
Charlotte Laurent
Nassim Kamar
Tristan de Nattes
Dominique Guerrot
Early Thrombotic Microangiopathy After ABO-Incompatible Living Donor Kidney Transplantation
Kidney International Reports
ABO-incompatible
antibody-mediated rejection
eculizumab
kidney transplantation
thrombotic microangiopathy
title Early Thrombotic Microangiopathy After ABO-Incompatible Living Donor Kidney Transplantation
title_full Early Thrombotic Microangiopathy After ABO-Incompatible Living Donor Kidney Transplantation
title_fullStr Early Thrombotic Microangiopathy After ABO-Incompatible Living Donor Kidney Transplantation
title_full_unstemmed Early Thrombotic Microangiopathy After ABO-Incompatible Living Donor Kidney Transplantation
title_short Early Thrombotic Microangiopathy After ABO-Incompatible Living Donor Kidney Transplantation
title_sort early thrombotic microangiopathy after abo incompatible living donor kidney transplantation
topic ABO-incompatible
antibody-mediated rejection
eculizumab
kidney transplantation
thrombotic microangiopathy
url http://www.sciencedirect.com/science/article/pii/S2468024924034776
work_keys_str_mv AT dominiquebertrand earlythromboticmicroangiopathyafteraboincompatiblelivingdonorkidneytransplantation
AT arnauddelbello earlythromboticmicroangiopathyafteraboincompatiblelivingdonorkidneytransplantation
AT rebeccasberrosoussan earlythromboticmicroangiopathyafteraboincompatiblelivingdonorkidneytransplantation
AT sophiecaillard earlythromboticmicroangiopathyafteraboincompatiblelivingdonorkidneytransplantation
AT guillaumeclaisse earlythromboticmicroangiopathyafteraboincompatiblelivingdonorkidneytransplantation
AT lionelcouzi earlythromboticmicroangiopathyafteraboincompatiblelivingdonorkidneytransplantation
AT sophiegirerd earlythromboticmicroangiopathyafteraboincompatiblelivingdonorkidneytransplantation
AT alexandrehertig earlythromboticmicroangiopathyafteraboincompatiblelivingdonorkidneytransplantation
AT yannicklemeur earlythromboticmicroangiopathyafteraboincompatiblelivingdonorkidneytransplantation
AT vincentpernin earlythromboticmicroangiopathyafteraboincompatiblelivingdonorkidneytransplantation
AT coraliepoulain earlythromboticmicroangiopathyafteraboincompatiblelivingdonorkidneytransplantation
AT cedricrafat earlythromboticmicroangiopathyafteraboincompatiblelivingdonorkidneytransplantation
AT mariematignon earlythromboticmicroangiopathyafteraboincompatiblelivingdonorkidneytransplantation
AT arnaudbuteux earlythromboticmicroangiopathyafteraboincompatiblelivingdonorkidneytransplantation
AT arnaudfrancois earlythromboticmicroangiopathyafteraboincompatiblelivingdonorkidneytransplantation
AT mathildelemoine earlythromboticmicroangiopathyafteraboincompatiblelivingdonorkidneytransplantation
AT charlottelaurent earlythromboticmicroangiopathyafteraboincompatiblelivingdonorkidneytransplantation
AT nassimkamar earlythromboticmicroangiopathyafteraboincompatiblelivingdonorkidneytransplantation
AT tristandenattes earlythromboticmicroangiopathyafteraboincompatiblelivingdonorkidneytransplantation
AT dominiqueguerrot earlythromboticmicroangiopathyafteraboincompatiblelivingdonorkidneytransplantation